Genethon to Present Groundbreaking Gene Therapy Advances in Rome
Genethon to Present Groundbreaking Gene Therapy Advances in Rome
Genethon is excited to announce the participation of 20 dedicated scientists at the prestigious European Society of Gene & Cell Therapy’s 31st Annual Congress, taking place from October 22 to 25, 2024. This important event offers a platform for Genethon to showcase the forefront of gene therapy research aimed at treating rare and serious diseases.
Sharing Innovative Research
Frederic Revah, Chief Executive Officer of Genethon, expressed enthusiasm about the event. He stated, "Participating in the ESGCT congress is a unique opportunity for our teams to share the latest results of Genethon’s work in the field of gene therapy. Our presentations will highlight both scientific and medical advances that have the potential to significantly improve patients' lives." This underscores Genethon’s commitment to leading the way in the development of transformative therapies.
Key Presentations
At the congress, Genethon will feature several significant oral presentations that represent their cutting-edge research. The schedule includes sessions dedicated to various aspects of gene therapy, focusing on advancements that improve efficacy and safety.
Wednesday, October 23
SESSION 3a: AAV vectors as tools in gene therapy of rare diseases (08:30 to 10:30)
Serge Braun will present data on GNT0004, focusing on the AAV8 vector-delivered microdystrophin gene therapy for Duchenne muscular dystrophy. This presentation will cover the first year's data from the Phase 1/2 clinical trial.
Additionally, SESSION 3d: Metabolic Diseases: Preclinical (08:30 to 10:30) will include insights from Louisa Jauze on liver-directed AAV gene transfer. This research has shown long-term correction of hypoglycemia in a GSDIII mouse model, highlighting the potential impacts of gene therapy.
Thursday, October 24
SESSION 7c: Cardio and Muscular (09:00 to 11:00) will feature Edith Renaud-Gabardos, who will discuss a ten-year efficacy study of gene therapy in a canine model of X-linked myotubular myopathy, demonstrating the persistent benefits of this treatment.
Later in the day, SESSION 9a: in vivo Gene Editing (15:30 to 17:30) will see Maelle Ralu present findings on CRISPR-Cas9 mediated strategies aimed at improving outcomes for patients with Duchenne muscular dystrophy.
Exciting Poster Presentations
In addition to oral presentations, Genethon will showcase 18 posters providing insights into various aspects of gene therapy research. This includes innovations in AAV vectors and their applications in treating genetic conditions.
AAV & Non-integrating vectors research will be highlighted by contributors like Valentina Buffa and Ricardo Rojas Gonzalez, focusing on the development of potency assays and purification processes.
Further, Sonia Albini will unravel the therapeutic efficacy of MIDI dystrophin variants, illustrating the progress in gene therapy for rare muscular diseases.
Contributions in areas such as metabolic diseases show the trajectory towards developing effective treatments for conditions like Farber disease, ensuring that each study presented is positioned to inform and inspire further research and application.
About Genethon
As a pioneer in gene therapy addressing rare diseases, Genethon was founded by AFM-Téléthon. It holds a prominent role in the gene therapy sector, with notable advancements in treatments that continue to change the lives of patients. With a dedicated team of over 200 professionals, the organization is involved in developing a variety of clinical trials for conditions affecting the liver, blood, immune system, muscles, and eyes. Their ongoing commitment aims at producing innovative therapies that radically alter patient care.
Frequently Asked Questions
What is Genethon?
Genethon is a non-profit organization focused on developing gene therapies for rare diseases, established by AFM-Téléthon.
What will Genethon present at the ESGCT congress?
Genethon will showcase oral presentations and posters detailing advancements in gene therapy, particularly for Duchenne muscular dystrophy and metabolic diseases.
Who is leading the presentations?
Leading Genethon's presentations will be key scientists like Frederic Revah, Serge Braun, Louisa Jauze, and others who are experts in their fields.
What types of diseases does Genethon focus on?
Genethon primarily focuses on rare genetic disorders affecting the liver, blood, immune system, muscles, and eyes.
How does Genethon influence gene therapy development?
Genethon impacts gene therapy by driving research and clinical trials dedicated to innovative treatments that improve patient care and outcomes.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Emirates Airlines Boosts Cargo Operations with New Freighters
- Edesa Biotech Announces Conference Engagements and Insights
- Celebrating Community Resilience at Harvest Nights Music Festival
- Loomis to Release Financial Report and Capital Markets Day
- What the Future Holds for Waymo and Tesla Without Ridesharing
- Experience the Latest Innovations from NEWTON GOLF at LD Micro
- Challenges Faced by Shell in Asset Sale to Renaissance Group
- Phunware's Upcoming Presentation Highlighting Innovations
- Political Uncertainty Fuels Gold Surge and Dollar Strength
- Why Netflix's Growth is Projected to Rise an Additional 15%
Recent Articles
- Elon Musk Voices Concerns on Space Travel Regulations During Campaign
- Tesla and Intel Respond to Mapping Allegations Amid Tensions
- Investors Face Massive Losses in Nvidia-Linked ETF Ahead of Growth
- Rently Enhances Rental Solutions with New Integrations
- HSBC Adjusts Axis Bank Price Target Amid Growth Challenges
- JPMorgan Downgrades RBL Bank Outlook, Concerns Over ROA Goals
- JPMorgan Adjusts Tata Consumer Products Price Target Amid Slump
- NexPoint Residential Receives Upgrade Amidst Rental Market Growth
- Boeing's Union Progress Sparks Optimism Amid Financial Challenges
- Nebius Group's AI Stock Launch: Volatility and Growth Potential
- DJI Takes Legal Action Against Pentagon Military Designation
- Ken Griffin's Top ETFs: SPDR S&P 500 and Invesco QQQ Insights
- Warren Buffett's Unstoppable Investments: Top Stock Picks Revealed
- Market Predictions: S&P 500 and Future Investment Trends
- Hand Cream Market Trends Indicate Growth to USD 1.43 Billion
- Exploring the Monthly NAV of WisdomTree's Investment Funds
- Understanding Debtor Distribution Data By Totalkredit A/S
- Nykredit Realkredit A/S Publishes Key Debtor Distribution Insights
- Man Group PLC Provides Insight on International Paper Stake
- Understanding Recent Disclosures from Man Group PLC
- Novo Nordisk Reveals Encouraging SOUL Trial Results on Heart Risks
- Vitalik Buterin's Insights on Cryptocurrency Growth Through Challenges
- Taiwan's Export Orders Show Mixed Signals Amid AI Boost
- Ongoing Oil Market Challenges Amid Geopolitical Easing
- Baird Upgrades Mohawk Industries Stock Amid Market Optimism
- Valmet Completes Negotiations to Strengthen Paper Business Line
- Citi Maintains Sell Rating on Tech Mahindra Despite Target Rise
- Citi Increases Hindustan Zinc's Price Target but Maintains Sell
- Citi Upgrades Polycab Target: Strong Growth Forecast Ahead
- Morgan Stanley Boosts BioAge’s Stock Potential Amid Partnerships
- Ally Financial Upgraded: Potential Recovery Amid Challenges
- How the Upcoming U.S. Elections Could Reshape Trade in Latin America
- Bigger Stock Gains: Insights from Morgan Stanley's Q3 Report
- Emirates Expands Fleet with New Boeing 777F Freighters
- Eli Lilly Takes Legal Action Against Sellers of Imitation Drugs
- Discover Exciting Small-Cap AI Stocks to Consider Now
- Corporate Governance Under Scrutiny Amidst WiseTech Shares Plunge
- Impacts of Federal Reserve's Rate Cut on Emerging Markets
- Plus Size Clothing Market Projected to Reach $178.2 Billion
- Alm. Brand A/S Resumes Share Buybacks: Weekly Overview
- BlackRock Canada Announces Cash Distributions for ETFs
- Gilat Satellite Networks to Discuss Innovative Q3 Results Soon
- Discover Glunz & Jensen's Upcoming Financial Announcements
- NUCLIDIUM Advances Prostate Cancer Imaging Breakthrough
- Q-nomy Inc. Enhances Customer Experience with Virtual Lobby 3.2.0
- Generative AI: Shaping the Future of Work in the U.K.
- Lufax's Q3 2024 Earnings Review: Financial Insights and Growth
- Rently Enhances Property Management with New Integrations
- Paladin Capital Group Elevates Nazo Moosa to Managing Director
- BMRT Secures $1.8 Billion Valuation, Poised for Market Impact